Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.
Yaning Wang, PhD
Advertisement
CEO, Createrna Science and Technology, former Director of FDA’s Division of Pharmacometrics
Articles by Yaning Wang, PhD
Collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.
Advertisement
Latest Updated Articles
PK in Late Phase TrialsPublished: February 1st 2012 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal
2
Securing Comparator Drugs in Competitive EU Markets: Challenges and Practical Solutions
3
Verana Health Merges With COTA to Expand Real-World Data Capabilities Across Oncology and Specialty Care
4
Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial
5